news

European Medicines Agency and German Society for Transfusion Medicine and Immunohaematology to co-organise workshop on advanced therapies

Posted: 19 May 2014 | | No comments yet

The European Medicines Agency’s Committee for Advanced Therapies and the German Society for Transfusion Medicine and Immunohaematology in collaboration with the German Stem Cell Network are organising a workshop to strengthen dialogue…

EMA

The European Medicines Agency’s Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohaematology (DGTI) in collaboration with the German Stem Cell Network (GSCN) are organising a workshop to strengthen dialogue between the CAT and the developers of advanced-therapy medicinal products (ATMPs), facilitating ATMP development and access to regulatory tools.

Entitled ‘How to bring cell-based medicinal products successfully to the market’, the workshop will take place at the Maritim Internationales Congress Centrum in Dresden, Germany, on 11 September 2014 as a satellite symposium of the DGTI Conference 2014External link icon.

The aim of the workshop is to provide ATMP developers, in particular academics and small companies, practical advice on the European authorisation procedure for ATMPs and the tools and support available to them.

“This is the third workshop that the CAT has co-organised with a learned society to promote development of ATMPs and raise awareness of the regulatory tools available,” explains Dr Paula Salmikangas, the Chair of the CAT. “Non-commercial sponsors and SMEs are the main developers of ATMPs. The aim of these workshops is to further support the translation of innovation into successful developments in the interest of patients.”

The workshop will give attendees the opportunity to:

  • learn about the development and authorisation of cell-based ATMPs in the European Union;
  • learn about the role of the CAT and the support provided by European Medicines Agency (EMA) and the CAT to ATMP developers;
  • understand the criteria that CAT applies for the classification of ATMPs;
  • hear about CAT’s considerations and recent interactions with experts on cell-based therapies for cardiac repair;
  • interact directly with the regulators in an open forum discussion.

For further information on the workshop and how to register, please see the DGTI Conference 2014 website.

Related organisations